SELLAS：SLS009 2期AML主要数据预计2026年第四季度发布

该公司宣布，在新诊断的一线AML的SLS009 2期试验中，80名计划患者中有28名已入组，主要数据预计于2026年第四季度发布。这确立了CDK9抑制剂项目的下一个临床读出里程碑。

关键事实

申报时间: 2026年8月11日 20:07
事件: 顶线结果
方向: 中性
公司: SLSSELLAS Life Sciences
资产: SLS009
来源: SEC 8-K
可信度: 有来源
试验规模: 80
已入组患者: 28

来源摘录

EX-99.1 2 sls-202608118xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - – 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 – – Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, NY, August 11, 2026 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceuti

SEC 8-K